Barbital (CRM) (Item No. 22854) is a certified reference material categorized as a barbiturate. Barbital is regulated as a Schedule IV compound in the United States. Barbital (CRM) (Item No. 22854) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.
Barbital is an analytical reference material that is categorized as a barbiturate. It acts as an agonist at GABAA receptors to induce central nervous system depression. Formulations containing barbital have been used as a sedative to treat insomnia and seizures in human and veterinary medicine. Barbital is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.
White crystals or powder; bitter taste;
odorless. Stable in air. Soluble in
hot water, alcohol, ether, acetone, and ethyl acetate.
Prototype of the barbiturate hypnotics.
ChEBI: A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).
Dormileno;Escoderm;Hypnogene;Hypnox;Lidor;Megal;Plexonal;Somnytic tablets;Verinogen;Verodon;Veroletten;Verolitten;Veronigen.
World Health Organization (WHO)
Barbital is a long-acting barbiturate which is controlled under
Schedule IV of the 1971 Convention on Psychotropic Substances. See WHO
comment for barbiturates.
(Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV),
, , 1971)
Poison by ingestion, intravenous,intraperitoneal, and subcutaneous routes. Ingestion causespsychological effects in humans. Mutation data reported.When heated to decomposition it emits toxic fumes ofNOx. An hypnotic andsedative.
Crystallise barbital from water or EtOH and dry it in a vacuum over P2O5. [Beilstein 24 III/IV 1901.]
[1] BRYAN H. NORMAN. Benzopyrans Are Selective Estrogen Receptor β Agonists with Novel Activity in Models of Benign Prostatic Hyperplasia[J]. Journal of Medicinal Chemistry, 2006, 49 21: 6155-6157. DOI:
10.1021/jm060491j[2] NESLIHAN ZENCIRCI. Crystal Polymorphs of Barbital: News about a Classic Polymorphic System[J]. Molecular Pharmaceutics, 2013, 11 1: 338-350. DOI:
10.1021/mp400515f[3] FRANCISCO LóPEZ-MUOZ Cecilio A Ronaldo Ucha Udabe. The history of barbiturates a century after their clinical introduction.[J]. Neuropsychiatric Disease and Treatment, 2005, 1 4: 329-343.
